JP2004531523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531523A5 JP2004531523A5 JP2002580954A JP2002580954A JP2004531523A5 JP 2004531523 A5 JP2004531523 A5 JP 2004531523A5 JP 2002580954 A JP2002580954 A JP 2002580954A JP 2002580954 A JP2002580954 A JP 2002580954A JP 2004531523 A5 JP2004531523 A5 JP 2004531523A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- amino
- a3rag
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/832,818 US20040204481A1 (en) | 2001-04-12 | 2001-04-12 | Activation of natural killer cells by adenosine A3 receptor agonists |
| PCT/IL2002/000298 WO2002083152A1 (en) | 2001-04-12 | 2002-04-11 | Activation of natural killer cells by adenosine a3 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004531523A JP2004531523A (ja) | 2004-10-14 |
| JP2004531523A5 true JP2004531523A5 (enExample) | 2005-06-30 |
Family
ID=25262686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002580954A Withdrawn JP2004531523A (ja) | 2001-04-12 | 2002-04-11 | アデノシンａ３レセプターアゴニストによるナチュラルキラー細胞の活性化 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040204481A1 (enExample) |
| EP (1) | EP1383515B1 (enExample) |
| JP (1) | JP2004531523A (enExample) |
| AT (1) | ATE284698T1 (enExample) |
| DE (1) | DE60202278T2 (enExample) |
| IL (1) | IL157841A0 (enExample) |
| WO (1) | WO2002083152A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| AR049384A1 (es) * | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| AU2005249430B2 (en) | 2004-05-26 | 2011-06-23 | Inotek Pharmaceuticals Corporation | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof |
| PL1778239T3 (pl) * | 2004-07-28 | 2014-01-31 | Can Fite Biopharma Ltd | Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena |
| US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
| CA2581132A1 (en) | 2004-09-20 | 2006-03-30 | Inotek Pharmaceuticals Corporation | Purine 5'-carboxamide derivatives and their use as adenosine receptor agonists |
| EP1819349A2 (en) * | 2004-11-22 | 2007-08-22 | King Pharmaceuticals Research and Development Inc. | Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| AU2006320578B2 (en) | 2005-11-30 | 2013-01-31 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
| GB0625100D0 (en) * | 2006-12-15 | 2007-01-24 | Univ Murcia | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
| US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| WO2010065959A1 (en) * | 2008-12-05 | 2010-06-10 | Northeastern University | Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy |
| ME02608B (me) | 2010-01-11 | 2017-06-20 | Inotek Pharmaceuticals Corp | Kombinacija, komplet i postupak snižavanja intraokularnog pritiska |
| CN102933593A (zh) | 2010-03-26 | 2013-02-13 | 伊诺泰克制药公司 | 使用n6-环戊基腺苷（cpa）、cpa衍生物或其前药降低人眼内压的方法 |
| SMT201800662T1 (it) | 2011-12-22 | 2019-01-11 | Alios Biopharma Inc | Nucleotidi, nucleosidi sostituiti e loro analoghi |
| US9278991B2 (en) | 2012-01-26 | 2016-03-08 | Inotek Pharmaceuticals Corporation | Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| BR112015021870A2 (pt) | 2013-03-15 | 2017-07-18 | Inotek Pharmaceuticals Corp | formulações oftálmicas |
| JP7474769B2 (ja) * | 2018-08-30 | 2024-04-25 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 一本鎖および多鎖キメラポリペプチドならびにその使用方法 |
| CN113365663B (zh) | 2018-08-30 | 2025-11-21 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| KR20250160211A (ko) | 2018-08-30 | 2025-11-11 | 이뮤니티바이오, 인크. | 다중-사슬 키메라 폴리펩타이드 및 이의 용도 |
| US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| JP7734693B2 (ja) | 2020-04-29 | 2025-09-05 | イミュニティーバイオ インコーポレイテッド | 抗ｃｄ２６タンパク質及びそれらの使用法 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL121272A (en) * | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
| IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
-
2001
- 2001-04-12 US US09/832,818 patent/US20040204481A1/en not_active Abandoned
-
2002
- 2002-04-11 DE DE60202278T patent/DE60202278T2/de not_active Expired - Fee Related
- 2002-04-11 EP EP02726402A patent/EP1383515B1/en not_active Expired - Lifetime
- 2002-04-11 IL IL15784102A patent/IL157841A0/xx unknown
- 2002-04-11 WO PCT/IL2002/000298 patent/WO2002083152A1/en not_active Ceased
- 2002-04-11 AT AT02726402T patent/ATE284698T1/de not_active IP Right Cessation
- 2002-04-11 JP JP2002580954A patent/JP2004531523A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004531523A5 (enExample) | ||
| JP2003514771A5 (enExample) | ||
| EP1027363B1 (en) | Adenosine a1-receptor agonists | |
| TWI866273B (zh) | 用於治療c型肝炎病毒的核苷酸半硫酸鹽 | |
| AU2011349278B2 (en) | Cyclic nucleotide analogs | |
| JP2006524711A5 (enExample) | ||
| JP2006515624A5 (enExample) | ||
| CA3214726A1 (en) | Nucleosides and nucleotides analogs as antiviral agents | |
| JPH11509181A (ja) | 水溶性アデノシンキナーゼ阻害剤 | |
| TW201217392A (en) | Substituted nucleotide analogs | |
| TW201808981A (zh) | 用於肝臟疾病之ｄ-胺基酸化合物 | |
| CZ282747B6 (cs) | Použití 1-/2-(hydroxymethyl)-1,3-oxathiazolan-5-yl/5-fluorocytosinu k výrobě léčiva pro ošetřování hepatitidy B | |
| WO2013142159A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| JP2004517864A (ja) | ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用 | |
| JP2004526720A5 (enExample) | ||
| AU2009200414A1 (en) | Compositions and methods for combination antiviral therapy | |
| JP2008505902A5 (enExample) | ||
| CA1333361C (en) | Antiviral compounds | |
| JPH06508846A (ja) | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療 | |
| JPH10139668A (ja) | ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用 | |
| KR900007833A (ko) | 신규 2^' -할로메틸리덴 2 -에테닐리덴 및 2 -에티닐 시티딘, 우리딘 및 구아노신 유도체 | |
| NO20024324D0 (no) | Legemidler for diagnose av vevsreproduktiv aktivitet eller behandling av proliferative sykdommer | |
| JPH0920659A5 (enExample) | ||
| JP2003520783A5 (enExample) | ||
| MXPA05010419A (es) | Compuestos para el tratamiento de infecciones por flaviviridae. |